InnoCare wins CDE nod for Phase III mesutoclax combo in r/r MZL
InnoCare Pharma has received approval from China's Centre for Drug Evaluation (CDE) to initiate a registrational Phase III trial of its oral BCL2 inhibitor mesutoclax (ICP-248) in combination with the BTK inhibitor orelabrutinib. The study targets patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior line of therapy, and represents the fifth registrational clinical trial now underway for mesutoclax.
The CDE sits within China's National Medical Products Administration (NMPA), and its approval of a registrational trial design signals that the agency is satisfied the programme is powered and structured to support a potential marketing authorisation. The approval follows a Breakthrough Therapy Designation (BTD) the NMPA had previously granted to the mesutoclax-orelabrutinib combination in the same relapsed or refractory MZL setting, which the company says is the first BCL2 inhibitor to receive that status in China.
Clinical data and mechanism
Mesutoclax works by selectively inhibiting BCL2, a protein that blocks programmed cell death in cancer cells. By restoring normal apoptosis, the drug is designed to complement the action of BTK inhibitors such as orelabrutinib, which target B-cell receptor signalling. Early combination data presented at the 2026 ASCO Annual Meeting showed an overall response rate of 100% in the relapsed or refractory MZL population, though the patient numbers underlying that figure were not disclosed in the company's announcement, and the dataset should be interpreted with caution until mature follow-up and a formal Phase III readout are available.
Co-founder and chief executive Jasmine Cui said mesutoclax had "rapidly advanced across multiple clinical programmes throughout China and globally," adding that the company aims to make it "a globally competitive innovative therapy" in haemato-oncology.
Beyond MZL, the mesutoclax programme is broad. A Phase III trial of mesutoclax plus orelabrutinib in first-line chronic lymphocytic leukaemia and small lymphocytic lymphoma has completed enrolment, as has a registrational Phase II study in BTK inhibitor-treated mantle cell lymphoma. A head-to-head Phase III study comparing mesutoclax plus azacitidine against the established venetoclax-azacitidine doublet in treatment-naive acute myeloid leukaemia is also underway in China, alongside global expansion in AML and myelodysplastic syndrome across the US and Australia.
Market context
MZL is the second most prevalent lymphoma in China, accounting for approximately 8.3% of all lymphoma diagnoses, and its annual incidence is rising globally. As an indolent B-cell non-Hodgkin's lymphoma, it predominantly affects middle-aged and older patients, a group with significant unmet need in the relapsed setting where durable remissions remain difficult to achieve.
The competitive landscape for BCL2 inhibition is dominated internationally by AbbVie and Roche's venetoclax, which holds approvals across multiple haematological malignancies. InnoCare is positioning mesutoclax as a differentiated alternative, and the head-to-head AML trial against venetoclax plus azacitidine is the clearest expression of that ambition. Whether mesutoclax can replicate or exceed venetoclax's efficacy profile in haematology indications will be the central question for investors and clinicians alike as Phase III datasets mature over the next two to three years. The outcome of the CLL enrolment-complete trial is likely to be the programme's first major value inflection point.